Kamil Ali-Jackson - Jan 3, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Legal Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 03:33 PM
Previous filing
Dec 17, 2021
Next filing
May 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +3.88K +3.38% 119K Jan 3, 2022 Direct F1
transaction ACRS Common Stock Options Exercise +27.9K +23.53% 146K Jan 3, 2022 Direct F1
transaction ACRS Common Stock Options Exercise +6.64K +4.53% 153K Jan 3, 2022 Direct F1
transaction ACRS Common Stock Options Exercise +7.1K +4.64% 160K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -3.88K -100% $0.00* 0 Jan 3, 2022 Common Stock 3.88K Direct F1, F2, F3
transaction ACRS Restricted Stock Units Options Exercise $0 -27.9K -100% $0.00* 0 Jan 3, 2022 Common Stock 34.4K Direct F1, F2, F4
transaction ACRS Restricted Stock Unit Options Exercise $0 -6.64K -100% $0.00* 0 Jan 3, 2022 Common Stock 19.9K Direct F1, F2, F5
transaction ACRS Restricted Stock Units Options Exercise $0 -7.1K -100% $0.00* 0 Jan 3, 2022 Common Stock 28.4K Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kamil Ali-Jackson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
F3 The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F4 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F5 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F6 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.